DHT Holdings Inc. vs Inovio Pharmaceuticals Inc — how do they compare? DHT Holdings Inc. trades at $24.98 (market cap $3.82B), while Inovio Pharmaceuticals Inc trades at $1.1 (market cap $119.42M). The key difference: DHT Holdings Inc. is far larger — about 32× Inovio Pharmaceuticals Inc's market cap, and DHT Holdings Inc. pays a 20.58% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DHT Holdings Inc. for 0 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DHT | INO | |
|---|---|---|
Market Cap | $3.82B | $119.42M |
Volume | 3,845,643 | 2,789,649 |
Sector | Industrials | Health |
52-Week High | $24.93 | $2.65 |
52-Week Low | $11.20 | $0.66 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $4.10B | $90.75M |
Dividend Yield | 20.58% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DHT Holdings operates a fleet of crude oil tankers that trade on international routes. Its fleet consists of very large crude carriers, or VLCCs.
Read more on DHT →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →